A Pilot Placebo Controlled, Double-Blind, Randomized Parallel Group Study to Evaluate the Efficacy of Treatment With CLR3001 in Depression.
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2015
At a glance
- Drugs CLR 3001 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Clera
- 03 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jul 2010 New trial record